- Boxer Dillian Whyte Returned Adverse Finding Which Saw Rematch With Anthony Joshua Cancelled
- The Drug Whyte Tested Positive For Has Never Been Revealed With Matchroom Silenced From Revealing
- NoSmokeSport Understands That Experimental Drug Molidustat Was Found In Whyte’s System By VADA
The Voluntary Anti-Doping Association (VADA) informed Matchroom Boxing on Saturday, August 5 that Dillian Whyte returned adverse analytical findings as part of a random anti-doping protocol.
As a result, his long-awaited DAZN pay-per-view rematch with Anthony Joshua at London’s O2 was cancelled with Robert Helenius stepping in at the 11h-hour to face AJ instead.
NoSmokeSport.com has now learnt that Whyte returned an adverse finding for an experimental drug ‘Molidustat‘.
Molidustat is a drug which can increase the endogenous production of erythropoietin (EPO).
Dillian Whyte Has Twice Previously Failed Drugs Tests
Whyte’s latest fail was the third occasion in which he had produced an adverse finding. Previously in 2012, the Jamaican-born athlete tested positive for methylhexaneamine (MHA) in a post-fight test.
The stimulant was contained in an over-the-counter supplement called Jack3D.
A tribunal ruled that Whyte did not knowingly take the substance but received a two-year ban on strict liability as the Heavyweight did not do enough due diligence on the supplement’s ingredients.
In 2019, UKAD withdrew a charge against Whyte after a thorough investigation accepted the former title challenger’s explanation of contamination for the presence of ‘trace amounts of metabolites’.